Table 3.
The comparison of the characters between male and female T2DM patients with thyroid nodule (n = 201).
| Variable | Male (n = 102, 50.7%) | Female (n = 99, 49.3%) | t values | P value |
|---|---|---|---|---|
| Age (years) | 58.46 ± 11.03 | 59.82 ± 9.35 | −0.94 | 0.348 |
| TSH (μIU/mL) | 1.99 ± 0.91 | 2.36 ± 1.06 | −2.663 | 0.008 |
| FT3 (pmol/L) | 4.58 ± 0.55 | 4.34 ± 0.49 | 3.306 | 0.001 |
| FT4 (pmol/L) | 17.05 ± 2.15 | 17.04 ± 2.05 | 0.034 | 0.973 |
| TPO (IU/mL) | 9.42 ± 4.74 | 9.35 ± 4.38 | 0.104 | 0.918 |
| HOMA-IR | 7.02 ± 6.69 | 9.42 ± 8.39 | −2.245 | 0.026 |
| Thyroid nodule volume (mL) | 0.18 ± 0.31 | 0.40 ± 0.67 | −2.978 | 0.003 |
| Thyroid nodule size (cm) | 0.70 ± 0.35 | 0.94 ± 0.50 | −2.926 | <0.001 |
HOMA-IR: homeostasis model assessment insulin resistance; TSH: thyroid stimulating hormone; FT4: free thyroxine; FT3: free triiodothyronine; HOMA-IR: homeostasis model assessment-insulin resistance.